BPC 157 for Acute Hamstring Muscle Strain Repair
Hudson Biotech120 participants2 Feb 2026 to est. 17 Feb 2028
Hamstring Muscle Strain · Skeletal Muscle Injury
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic fragment BPC-157 | Synthetic fragment TB-500 | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic fragment | Synthetic fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 987 | 36 | |
| Evidence level | Has results from studies in people | Results from animal studies onlyRegistered trials, no results from human studies | |
| Safety | |||
| Safety results | 24 (8 in people) | 1 (0 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 3 · 2 active1 more mentions it but does not test it | 1 · 1 active | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | BPC-157 | TB-500 |
|---|---|---|
| Wound healingSkin and wound | 1301228 | 826 |
| Neuroprotection |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 1. The FDA, the EMA and the other sources we use show no approval (as of 30 Oct 2026).
7474 |
853 |
| Tendon and ligament healingMusculoskeletal | 463511 | 88 |
|---|
| Adverse eventsWhole body | 24816 | 11 |
|---|
| Inflammation markersWhole body | 4141 | 413 |
|---|
| PharmacokineticsPharmacology | 871 | 541 |
|---|
| Cognition and memoryNervous system and cognition | 22 | 22 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
TB-500 is the same as Thymosin beta-4 (human) residues 17 to 23, with 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
3 trials · 1 ongoing · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)
Hudson Biotech120 participants2 Feb 2026 to est. 17 Feb 2028
Hamstring Muscle Strain · Skeletal Muscle Injury
PharmaCotherapia d.o.o.42 participantsOct 2015 to est. Mar 2016
Healthy Volunteers
University of Arkansas30 participantsest. 1 Jan 2027 to est. 1 Aug 2027
Rotator Cuff Tear
1 more mentions it but does not test it. They only measure it or name it in their text.
1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)
Hudson Biotech80 participants5 Feb 2026 to est. 17 Feb 2028
Atherosclerotic Cardiovascular Diseases · Endothelial Dysfunction